[1]
|
Konstantinopoulos, P.A. and Matulonis, U.A. (2023) Clinical and Translational Advances in Ovarian Cancer Therapy. Nature Cancer, 4, 1239-1257. https://doi.org/10.1038/s43018-023-00617-9
|
[2]
|
Dedecker, H., Teuwen, L.-A., Vandamme, T., et al. (2023) The Role of Immunotherapy in Esophageal and Gastric Cancer. Clinical Colorectal Cancer, 22, 175-182. https://doi.org/10.1016/j.clcc.2023.03.001
|
[3]
|
Caruso, G., Tomao, F., Parma, G., et al. (2023) Poly(ADP-Ribose) Polymerase Inhibitors (PARPi) in Ovarian Cancer: Lessons Learned and Future Directions. International Journal of Gynecologic Cancer, 33, 431-443. https://doi.org/10.1136/ijgc-2022-004149
|
[4]
|
Sánchez-Magraner, L., Gumuzio, J., Miles, J., et al. (2023) Functional Engagement of the PD-1/PD-L1 Complex but Not PD-L1 Expression Is Highly Predictive of Patient Response to Immunotherapy in Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 41, 2561-2570. https://doi.org/10.1200/JCO.22.01748
|
[5]
|
Long, G., Khattak, A., et al. (2022) KEYNOTE-D36: Personalized Immunotherapy with a Neoepitope Vaccine, EVX-01 and Pembrolizumab in Advanced Melanoma. Future Oncology, 18, 3473-3480. https://doi.org/10.2217/fon-2022-0694
|
[6]
|
Peng, Z., Li, M., Li, H., et al. (2023) PD-1/PD-L1 Immune Checkpoint Blockade in Ovarian Cancer: Dilemmas and Opportunities. Drug Discovery Today, 28, Article ID: 103666. https://doi.org/10.1016/j.drudis.2023.103666
|
[7]
|
Liu, P., Chen, R., Zhang, X., et al. (2022) Combined PD-1/PD-L1 and Tumor-Infiltrating Immune Cells Redefined a Unique Molecular Subtype of High-Grade Serous Ovarian Carcinoma. BMC Genomics, 23, Article No. 51. https://doi.org/10.1186/s12864-021-08265-y
|
[8]
|
Hamanishi, J., Mandai, M., Ikeda, T., et al. (2015) Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients with Platinum-Resistant Ovarian Cancer. Journal of Clinical Oncology, 33, 4015-4022. https://doi.org/10.1200/JCO.2015.62.3397
|
[9]
|
Hamanishi, J., Takeshima, N., Katsumata, N., et al. (2021) Nivolumab versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients with Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA). Journal of Clinical Oncology, 39, 3671-3681.
|
[10]
|
Zamarin, D., Burger, R.A., Sill, M.W., et al. (2020) Randomized Phase II Trial of Nivolumab versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study. Journal of Clinical Oncology, 38, 1814-1823. https://doi.org/10.1200/JCO.19.02059
|
[11]
|
Matulonis, U.A., Shapira-Frommer, R., Santin, A.D., et al. (2019) Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase II KEYNOTE-100 Study. Annals of Oncology, 30, 1080-1087. https://doi.org/10.1093/annonc/mdz135
|
[12]
|
Walsh, C.S., Kamrava, M., Rogatko, A., et al. (2021) Phase II Trial of Cisplatin, Gemcitabine and Pembrolizumab for Platinum-Resistant Ovarian Cancer. PLOS ONE, 16, E0252665. https://doi.org/10.1371/journal.pone.0252665
|
[13]
|
Konstantinopoulos, P.A., Waggoner, S., Vidal, G.A., et al. (2019) Single-Arm Phases 1 and 2 Trial of Niraparib in Combination with Pembrolizumab in Patients with Recurrent Platinum-Resistant Ovarian Carcinoma. JAMA Oncology, 5, 1141-1149. https://doi.org/10.1001/jamaoncol.2019.1048
|
[14]
|
Zsiros, E., Lynam, S., Attwood, K.M., et al. (2021) Efficacy and Safety of Pembrolizumab in Combination with Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial. JAMA Oncology, 7, 78-85. https://doi.org/10.1001/jamaoncol.2020.5945
|
[15]
|
Liu, J.F., Gordon, M., Veneris, J., et al. (2019) Safety, Clinical Activity and Biomarker Assessments of Atezolizumab from a Phase I Study in Advanced/Recurrent Ovarian and Uterine Cancers. Gynecologic Oncology, 154, 314-322. https://doi.org/10.1016/j.ygyno.2019.05.021
|
[16]
|
Moore, K.N., Bookman, M., Sehouli, J., et al. (2021) Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG3015/ENGOT-OV39). Journal of Clinical Oncology, 39, 1842-1855. https://doi.org/10.1200/JCO.21.00306
|
[17]
|
Ak, N. and Vatansever, S. (2021) Dramatic Response to Single-Agent Atezolizumab in a Patient with MSI-H Serous Ovarian Cancer. Journal of Clinical Pharmacy and Therapeutics, 46, 1787-1791. https://doi.org/10.1111/jcpt.13364
|
[18]
|
Moroney, J.W., Powderly, J., Lieu, C.H., et al. (2020) Safety and Clinical Activity of Atezolizumab plus Bevacizumab in Patients with Ovarian Cancer: A Phase Ib Study. Clinical Cancer Research, 26, 5631-5637. https://doi.org/10.1158/1078-0432.CCR-20-0477
|
[19]
|
Rocconi, R.P., Stevens, E.E., Bottsford-Miller, J.N., et al. (2022) Proof of Principle Study of Sequential Combination Atezolizumab and Vigil in Relapsed Ovarian Cancer. Cancer Gene Therapy, 29, 369-382. https://doi.org/10.1038/s41417-021-00317-5
|
[20]
|
Simonelli, M., Garralda, E., Eskens, F., et al. (2022) Isatuximab plus Atezolizumab in Patients with Advanced Solid Tumors: Results from a Phase I/II, Open-Label, Multicenter Study. ESMO Open, 7, Article ID: 100562. https://doi.org/10.1016/j.esmoop.2022.100562
|
[21]
|
Zamarin, D., Walderich, S., Holland, A., et al. (2020) Safety, Immunogenicity, and Clinical Efficacy of Durvalumab in Combination with Folate Receptor Alpha Vaccine TPIV200 in Patients with Advanced Ovarian Cancer: A Phase II Trial. The Journal for ImmunoTherapy of Cancer, 8, e000829. https://doi.org/10.1136/jitc-2020-000829
|
[22]
|
Lampert, E.J., Zimmer, A., Padget, M., et al. (2020) Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: A Proof-Of-Concept Phase II Study. Clinical Cancer Research, 26, 4268-4279. https://doi.org/10.1158/1078-0432.CCR-20-0056
|
[23]
|
Ngoi, N.Y., Heong, V., Ow, S., et al. (2020) A Multicenter Phase II Randomized Trial of Durvalumab (MEDI-4736) versus Physician’s Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA). International Journal of Gynecological Cancer, 30, 1239-1242. https://doi.org/10.1136/ijgc-2020-001604
|
[24]
|
Monk, B.J., Colombo, N., Oza, A.M., et al. (2021) Chemotherapy with or without Avelumab Followed by Avelumab Maintenance versus Chemotherapy Alone in Patients with Previously Untreated Epithelial Ovarian Cancer (JAVELIN Ovarian 100): An Open-Label, Randomised, Phase 3 Trial. The Lancet Oncology, 22, 1275-1289. https://doi.org/10.1016/S1470-2045(21)00342-9
|
[25]
|
Pujade-Lauraine, E., Fujiwara, K., Ledermann, J.A., et al. (2021) Avelumab Alone or in Combination with Chemotherapy versus Chemotherapy Alone in Platinum-Resistant or Platinum-Refractory Ovarian Cancer (JAVELIN Ovarian 200): An Open-Label, Three-Arm, Randomised, Phase 3 Study. The Lancet Oncology, 22, 1034-1046. https://doi.org/10.1016/S1470-2045(21)00216-3
|